Hypercortisolism Impact on Hypertension and Hyperglycemia and Beyond
Ralph A. DeFronzo • 2024 • Heart in Diabetes 2024
Posted with permission of the presenter.
© 2024 Corcept Therapeutics, Incorporated
Medical Treatment of Hypercortisolism with Relacorilant: Final Results of the Phase 3 GRACE Study
2024 • Heart in Diabetes 2024
Rapid Clinical Improvements in a Patient with Difficult-to-Control Type 2 Diabetes by Addressing Underlying Hypercortisolism with Mifepristone
2024 • AACE 2024
Impact of Surgery or Medical Treatment With the Selective Glucocorticoid Receptor Modulator Relacorilant on Hypercoagulopathy in Patients With Cushing Syndrome
Simeoli et al. • 2023 • Italian Society of Endocrinology National Congress 2023
Impact of Surgery or Medical Treatment With the Selective Glucocorticoid Receptor Modulator Relacorilant on Hypercoagulopathy in Patients With Cushing Syndrome
Simeoli et al. • 2023 • ENDO 2023
A Phase 4 Study of Hypercortisolism in Patients with Difficult-to-Control Type 2 Diabetes Despite Receiving Standard-of-Care Therapies, Assessing Prevalence and Treatment with Mifepristone
Frias et al. • 2023 • ENDO 2023
A Phase 4 Study of Hypercortisolism in Patients with Difficult-to-Control Type 2 Diabetes Despite Receiving Standard-of-Care Therapies, Assessing Prevalence and Treatment with Mifepristone
Frias et al. • 2023 • 7th annual Heart in Diabetes CME Conference
https://corcept.com/wp-content/uploads/2023/07/ECE2023-1.pdf
Simeoli et al. • 2023 • European Congress of Endocrinology